
|Articles|October 19, 2013
- B-Cell Malignancies
- Volume 1
- Issue 1
Emerging Therapies for the Treatment of Mantle Cell Lymphoma
Author(s)Ari M. Melnick, MD
Ari M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Advertisement
Ari M. Melnick, MD, from Weill Cornell Medical College, comments on emerging therapies for the treatment of mantle cell lymphoma.
Articles in this issue
about 12 years ago
Updated Data for Pomalidomide in Relapsed/Refractory Multiple Myelomaabout 12 years ago
Clinical Advances in Mantle Cell Lymphomaabout 12 years ago
In Brief: Phase III Trials in Multiple Myelomaabout 12 years ago
Therapy for CLL: Where Are We Today? Where Will We Be Tomorrow?about 12 years ago
BTK and PI3K Inhibitors in Development for Chronic Lymphocytic Leukemiaabout 12 years ago
Transforming Expectations and Outcomes With Targeted Therapiesabout 12 years ago
The Utility of Pomalidomide in R/R Multiple Myelomaabout 12 years ago
Dr. Zelenetz Discusses Diagnosis and Treatment Issues in Indolent NHLAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
3
Pelareorep Offers Promise in Second-Line KRAS-Mutant Metastatic CRC
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5










































